---
title: "Atrioventricular interval modulation therapy granted US FDA breakthrough designation"
date: "2025-04-22T13:43:24.000Z"
publishedDate: "22 avril 2025"
summary: "Orchestra BioMed Holdings has announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation for atrioventricular interval modulation (AVIM) therapy. The breakthrough device designation is for an implantable system (i.e."
importance: ""
sourceUrl: "https://cardiovascularnews.com/atrioventricular-interval-modulation-therapy-granted-us-fda-breakthrough-designation/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-04-22-atrioventricular-interval-modulation-therapy-granted-us-fda-breakthrough-designation"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/06/blood-pressure.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/atrioventricular-interval-modulation-therapy-granted-us-fda-breakthrough-designation/"
---

![Atrioventricular interval modulation therapy granted US FDA breakthrough designation](https://cardiovascularnews.com/wp-content/uploads/sites/14/2023/06/blood-pressure.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/atrioventricular-interval-modulation-therapy-granted-us-fda-breakthrough-designation/*

## L’essentiel

Orchestra BioMed Holdings has announced that the US Food and Drug Administration (FDA) has granted breakthrough device designation for atrioventricular interval modulation (AVIM) therapy. The breakthrough device designation is for an implantable system (i.e.

## Lien source

https://cardiovascularnews.com/atrioventricular-interval-modulation-therapy-granted-us-fda-breakthrough-designation/
